

Reducing Unnecessary Regulatory Burdens (RURB) in Pharmaceutical Industry: Engagement with Pharmaceutical Association of Malaysia (PhaMA)

30 October 2020, 3.30pm

Attendees:

Mr. Mohd Hilmi Mohd Idris	MPC
Mrs. Anis Marina Abd Wahab	MPC
Mr. Ahmad Zaidi Abd. Wahab	MPC Associate
Dr. Yogesvari Sambasevam	MPC Associate
Ms. Alice Chee Seat Mee	PhaMA
Ms. Janice Tan	Novartis Corporation (M) Sdn. Bhd.
Ms. Ta Su May	DKSH Malaysia
Ms. Stephanie Ong	Sanofi-Aventis (Malaysia) Sdn. Bhd.
Ms. Long Siew Mei	Merck Sharp & Dohme (MSD) Malaysia
Ms. Nesha Armo	Merck Sharp & Dohme (MSD) Malaysia
Ms. Sebrina Su	AstraZeneca Sdn. Bhd.

Adalah dengan ini diperakukan perkhidmatan seperti berikut:-



Mohamad Azrol Md Dali
Timbalan Pengarah
Perbadanan Produktiviti Malaysia
Tel: 03-7955 7266

RURB Study on Pharmaceutical Industry: Engagement with Industry
01:35:02
Request control
Participants

6. Multiple Agency Approvals

Issue	Remarks	Suggestion
Medical Device Authority (MDA) & National Pharmaceutical Regulatory Agency (NPRA) Registration for Medical Device-Drug (combined product)	Have to register the finished products with both NPRA and MDA. Time consuming.	Register only with NPRA

Questions

- ☐ How many products/companies involved with the issue?
- ☐ Is there any other related products/process?
- ☐ Benchmark with other countries' best practices?
- ☐ Rationale for suggestion/recommendation?

Anis Marina Abd Wahab

+4
SO
SL
Z
JT
A
YS

Zaidi (Guest)
Tan, Janice
Alice (Guest)

Participants

Type a name

- YS Yogeswari Sambasevam
- A Alice (Guest) Guest
- AW Anis Marina Abd Wahab
- NA ARMO, NESHA Outside your organization
- SL Long, Siew Mei Outside your organization
- MI Mohd Hilmi Mohd Idris Organizer
- SO Ong, Stephanie /MY Outside your organization
- SS Su, Sebrina Outside your organization
- JT Tan, Janice Outside your organization
- Z Zaidi (Guest) Guest